In 1982, after investing eight years of effort, Pfizer was preparing to end its work in macrolide research. Its work in finding an improved version of erythromycin had come up empty. But, as happens ...
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended several changes to the way the antibiotic azithromycin is used in the EU, including the removal of certain indications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results